The US government has placed an order with Merck & Co to buy 1.7 million courses of its antiviral therapy molnupiravir for COVID-19, assuming it gets approved for use by the FDA.
UK biotech Inspira Pharmaceuticals has emerged from stealth mode with a deal with Vectura to develop an inhaled therapy for COVID-19 that could be ready for human testing within 12 months.&
The European Commission has given a green light to the use of ViiV Healthcare’s Rukobia as a treatment for people with HIV that has developed resistance to other antiretroviral therapy (ART
US biotech BioSig Technologies has abandoned a phase 2 trial of its antiviral drug merimepodib with Gilead’s Veklury in severe COVID-19 patients, after concluding the safety of the combinat
The first healthy volunteers have started to receive doses of Gilead’s inhaled formulation of remdesivir, which it hopes could become an option for earlier-stage COVID-19 outsi
The FDA has approved Rukobia, a first-in-class drug from ViiV Healthcare intended for older people with HIV, who have been on antiretroviral therapy (ART) for so long it is sta